Skip to content
TickerMagic

Gland Pharma Limited

GLANDNSEHealthcare
₹3,292.9
+62.40 (+1.93%) · EOD 2026-11-20

Our verdict

Buy

Financial trend (92/100) does the heavy lifting; valuation (40/100) is the drag.

Buy zoneHealth A
Quality 75Momentum 84Value 40Trend 92The Spark ↓

Our fair value

Overvalued by 21%
₹2,608.24down 20.79%
Price ₹3,293Range ₹1,646 – ₹2,992

Buy-below (20% margin of safety): ₹2,086.59

The bottom line

Gland Pharma Limited earns a Buy from TickerMagic, with a blended score of 70/100. At ₹3,292.9 it trades above our blended DCF and relative-multiples fair value of ₹2,608.24, about 21% downside to that estimate — we read it as overvalued by 21%. On 37.4x trailing earnings it sits roughly in line with the Healthcare median of about 37.4x. It's trading right at its 52-week high of ₹3,385.9. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 8/9. The average analyst target of ₹2,189.57 implies about 34% downside across 14 analysts. It clears 10 of 13 investability checks, with durability 75, valuation 65 and momentum 84 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹2,608.24down 20.79%
Overvalued by 21%
Price ₹3,292.9Range ₹1,646.45–₹2,992.26
DCF + relative blendhigh confidence

With a 20% margin of safety, our buy-below price is ₹2,086.59.

Analyst views

14 analysts10 buy · 1 hold · 3 sell
12-month consensus target₹2,189.57down 33.51%

1-year price

EOD · 2026-11-20
1D
up 1.93%
1W
down 0.48%
1M
up 9.04%
3M
up 15.19%
6M
up 47.38%
1Y
—

52-week range

-2.75% from the 52-week high.

Trend check
Above 50-DMA₹3,038Above 200-DMA₹2,364

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Buy70
A
Financial health 100/100
Altman Z 12.58 · Safe zone

Piotroski F-score 8/9 — quality of earnings & balance sheet.

Our scores

Durability75
Valuation65
Momentum84

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 10 of 13 checks
Each check screens one fundamentals, valuation or trend signal.
  • Fail: ROE above 15%: 10.5%
  • Pass: Low debt (D/E < 0.5): 0.03x
  • Pass: Positive free cash flow
  • Pass: Revenue growth > 10%: 22%
  • Pass: Earnings growing: 96%
  • Pass: Net margin ≥ 10%: 16.0%
  • Pass: Current ratio > 1.5: 4.68
  • Fail: Below our fair value
  • Fail: Margin of safety ≥ 20%
  • Pass: Above 200-day average
  • Pass: Above 50-day average
  • No data: Positive 1-year return
  • Pass: Altman Z in safe zone: Z 12.58
  • Pass: Piotroski ≥ 7: 8/9

Quarterly results

Revenue · 1Q2026
₹1,743 Cr
Net profit
₹367 Cr
Margin
21%
2Q2025
3Q2025
4Q2025
1Q2026
Revenue Net profitLatest revenue QoQ +3%

Annual financials

Revenue · 2026
₹6,431 Cr
Net profit
₹1,046 Cr
Margin
16%
2023
2024
2025
2026
Revenue Net profitLatest revenue YoY +14%

Shareholding

  • Promoter51.8%
  • Institutions36.3%
  • Public & other11.9%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹38,373 Cr
P/E ratio
37.4
P/B ratio
3.70
EPS (TTM)
₹62.28
ROE
10.5%
Debt / Equity
0.03x
Profit margin
16.0%
Free cash flow
₹504 Cr
52-week high
₹3,385.9
-2.75% from high
52-week low
₹1,584.83
Dividend yield
0.9%
Beta
0.50
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Lightly leveraged balance sheet.
  • Healthy profit margin (16.0%).
  • Trading near its 52-week high.
  • Financially solid — Altman Z 12.58.
  • High Piotroski quality score (8/9).

Opportunities

  • Earnings growing (96% YoY).
  • Revenue growing (22% YoY).
  • Trading in our value buy zone versus sector peers.

Bear case

Threats

  • Trades ~21% above our estimated fair value.

About Gland Pharma Limited

Gland Pharma Limited manufactures and sells injectable formulations globally, including in India, the United States, Europe, Canada, Australia, and New Zealand. The company develops active pharmaceutical ingredients through synthesis of complex molecules such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic compounds for various therapeutic categories.

Gland Pharma Limited — frequently asked questions

Is Gland Pharma Limited a buy, hold or sell?

TickerMagic currently rates Gland Pharma Limited (GLAND) a Buy, based on a blended score of 70/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is Gland Pharma Limited's fair value?

Our blended DCF and relative-valuation model estimates Gland Pharma Limited's fair value at about ₹2,608.24, versus a current price of ₹3,292.9 — roughly 21% downside. On that basis the stock looks overvalued by 21%.

Is Gland Pharma Limited financially healthy?

Gland Pharma Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 8/9.

How has Gland Pharma Limited's share price performed?

Gland Pharma Limited is up 15% over three months, and last traded at ₹3,292.9. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.